Drugs / ISL/LEN FDC
last change Dec 2023 re-read 2 minutes ago

ISL/LEN FDC

Developed for
HIV infectious disease
Investigated by
Gilead Sciences · Merck Sharp & Dohme LLC

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT05052996 Oct 2021 → Dec 2023 overdue HIV infectious disease Gilead Sciences Active not recruiting No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ISL/LEN FDC ClinicalTrials.gov intervention name — accepted as the source's own label NCT05052996